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Abstract: 
The magnitude of the problems of drug abuse and Neuro-AIDS warrants the development of novel approaches for testing hypotheses in 
diagnosis and treatment ranging from cell culture models to developing databases.  In this study, cultured neurons were treated 
with/without HIV-TAT, ENV, or cocaine in a 2x2x2 expression study design. RNA was purified, labeled, and expression data were 
produced and analyzed using ANOVA.  Thus, we identified 35 genes that were significantly expressed across treatment conditions. A 
diagram is presented showing examples of molecular relationships involving a significantly expressed gene in the current study (SOX2). 
Also, we use this information to discuss examples of gene expression interactions as a means to portray significance and complexity of 
gene expression studies in Drug Abuse and Neuro-AIDS.  Furthermore, we discuss here that critical interactions remain undetected, which 
may be unravelled by developing robust database systems containing large datasets and gleaned information from collaborating scientists . 
Hence, we are developing a public domain database we named The Agora database , that will served as a shared infrastructure to query, 
deposit, and review information related to drug abuse and dementias including Neuro-AIDS.  A workflow of this database is also outlined 
in this paper. 
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Background: 
HIV-1 is frequently detected in the brain of HIV-1 infected 
individuals. [1] The exposure of neural cells to some drugs, HIV-1 
proteins or HIV-1 infection may cause brain damage and perturb gene 
expression. In neural cells, the toxicity of the HIV-1 proteins gp120 
and TAT was shown to involve Ca+2 and glutamate channels, and it 
could be reversed by memantine. Furthermore, cocaine stimulates 
HIV-1 replication through the chemokine, cytokine, and signaling 
pathways. [2, 3] Drug abuse and HIV-1 infection most likely enhance 
neuropsychiatric disease, HAD (HIV associated Dementia), and HIVE 
(HIV encephalitis) as shown elsewhere. [4, 5] During the early course 
of HIV-1 infection, the virus penetrates the blood-brain barrier (BBB). 
[6] HIV-1 invasion of the brain most likely occurs via macrophage 
and microglial cells and this leads to HIVE. [2, 7] Recent work 
describes the influx of CD16-positive macrophages from bone 
marrow into the brain. [8] Several inflammatory molecules including 
cytokines, chemokines (CCKs), growth factors, lipids, and excitatory 
compounds are associated with brain inflammation and damage. [9, 
10] Here, we provide a preliminary description of the molecular 
mechanisms underlying these processes using expression and gene 
annotation data.  This information has been stored in a user friendly, 
online database which will be made available to the public domain. 
 
Methodology: 
Cultured human fetal neurons were isolated, cultured, and treated with 
HIV-1 TAT, HIV-1 ENV and cocaine in a 2x2x2 study design. [5, 11, 
12] The Affymetrix HGU95A oligonucleotide chip was used to 
measure the expression of 12,565 probes. The data were analyzed 
using a one-way ANOVA (analysis of variance) among the eight 
treatment groups across genes (p < 0.0005). The expression of 35 
genes was statistically significant. [5] We then used Pathways 
Assist (Stratagene, Inc.) to portray pathways among genes through 
common and divergent relationships. We modeled the neurological 
processes involved in Drug Abuse and Neuro-AIDS by 
computational simulation of physiological processes using 
experimentally derived information.  
 
Our model uses the representation of biochemical networks 
named Moirai that is described elsewhere. [13] The clinical and 
physiological features are represented as sub-networks that 
recursively expand to their known component reactions, 
recorded pertinent data based on functional assays, and 
information on cell/tissue types. These features are treated as 
containers for cellular compartments in anatomical structures. 
Thus, our model mixes information known at varying levels 
occurring at different spatial and logical scales. We then use a 
prototype version of The Agora to populate the computational 
model where the information entered in forms goes into the 
model after appropriate review. [14] The development of The 
Agora is in progress and the completed version when made 
available in the public domain will enable scientists to retrieve 
biochemical and physiological information on Neuro-AIDS. We 
use the language semantics in Glossa for gene to pathway 
mapping in this development. [15] 
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Figure 1: (A) Gene interactions using Ariadne Pathways AssistTM. This figure shows relationships among genes expressed in neurons in 
culture as an example of possible gene expression network connections. Connections from SOX-2, a central transcription factor/regulator are 
shown to nuclear (e.g. SOX1, SOX3, etc.) and membrane associated proteins (e.g. FGF4, FGF3, etc). (B) Modeling drug abuse and 
neurological phenomena. This figure illustrates the iterative process of adumbrating a representation (top box), populating it with 
experimental data (middle box), and using the populated representation to develop and test hypotheses (lowest box). Each of these steps 
interacts, but one cannot proceed to simulation until the first two have advanced sufficiently to provide an adequate initial model.  
 
Results: 
Thirty-five (35) genes were previously identified by ANOVA 
analysis of gene expression results from neuron cultures treated with 
cocaine/TAT/ENV. [5] The Ariadne Pathways AssistTM program 
was then used to generate annotated pathway interactions among 
gene products. The categories of genes thus generated and with 
which they interact include inflammation, focal contact, 
proliferation and growth, motility, morphogenesis, shape, 
mitogenesis, synaptogenesis, differentiation, cell survival, and 
neuropsychiatric disease. In Figure 1A, we see that SOX2, a 
transcription factor, interacts with other transcription factors (e.g. 
SOX1, SOX3, etc.) in the nucleus and also promotes the expression 
of cell surface growth factor receptors (e.g. FGF4, FGF3, etc). This 
is interpreted as a series of reparative processes attempted by the 
neuron under stress due to exposure to TAT, ENV and cocaine. 
 
Interpreting results such as those reported here in a physiological 
and clinical context requires building and refining computational 
models for specific clinical conditions. There are three steps in the 
modeling process that continuously and cyclically interact (Figure 
1B). First, one must computationally represent the phenomena in 
a way that accurately captures the biology, biochemical and 
physiological data, including information on cells, compartments, 
and tissues, and supports simulations of biological phenomena. 
Our current model focuses on phenomena relevant to drug abuse 
and several dementias including NeuroAIDS. Second, one must 
populate that representation with experimental data to form the 
basic model. We are using a prototype version of The Agora, a 
planned public resource for the scientific community to curate and 
use their biochemical and physiological databases to populate our 
computational model. We enrich the model with new relationships 
and types of information as the data entry process proceeds. For 
example, we initially did not include information on molecular 
biology kits, but these turned out to be important ways of 
specifying certain experimental protocols. Third, one develops 
and tests hypotheses about the phenomena by modifying the 
model and simulating the results. Until the basic model 
satisfactorily captures both the biological ideas (the 
representation) and the data, one cannot embark on this stage. 
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Once simulations commence, the representations are likely to 
change in response to the results. 
 
Discussion: 
Drug abuse is a complicating factor in the diagnosis and treatment of 
HAD and related diseases. [4, 16] The preliminary gene expression 
study in cultured neurons treated with cocaine and HIV-1 proteins is 
described as a useful controlled model. We previously analyzed 
gene expression related to AIDS directly in gross brain tissue 
(without cell fractionation or micro-dissection) and in cell culture. 
[5, 17] In these brain gene expression studies, statistical hypothesis 
testing was used to identify genes that are differentially expressed 
between two groups, HIV+ cases and HIV- controls. [17] However, 
we did not use traditional hypothesis testing methods as these are 
insufficient given the extremely large number of tests involved. 
Since there are over 12,000 genes to be tested, the expected number 
of Type I errors (false positives) becomes unacceptable.    
 
The preliminary analysis of the human neuron gene expression using 
the one-way ANOVA produced a list of 35 genes that were 
significantly expressed across treatments. Application of a GLM 
analysis for significant interactions indicated most of these genes 
were significant due to TAT, some due to TAT-ENV, TAT-cocaine, 
and ENV-cocaine interactions, and none due to TAT-ENV-cocaine 
interactions. [5] During the course of generating Figure 1A, 113,944 
sequence objects were examined in the Ariadne database in order to 
identify the genes and their interactions and connections indicated in 
the figure. In this figure we see examples of extensive interactions 
that occur among transcription factors in the nucleus (SOX1, 
SOX2, SOX3, etc) as well as with cell surface growth factor 
receptors (e.g. FGF4, FGF3, etc). This is interpreted as a series of 
reparative processes attempted by the neuron under stress due to 
exposure to tat, env, and cocaine. 
 
The preliminary analyses described here are part of a wider scope 
needed to defeat drug abuse, Neuro-AIDS, and other Dementias.  
[3]  Computational modeling of biological phenomena serves 
three main purposes including to express what is known, to help 
formulate hypotheses, and to test those hypotheses. Large 
amounts of data are produced in diverse studies including 
molecular biology, drug abuse, virology, immunology, 
physiology, computational biology, and statistics. The vast 
majority of data needed to explore hypotheses and to interpret the 
results of these efforts for the most part remains locked in the 
print literature and posted web-sites. [18, 19, 20, 21, 22, 23, 24, 
25, 26] We are currently using The AGORA to record this data 
related to Drug Abuse and Neuro-AIDS and other neurological 
diseases. [4] We are developing methods to structure anatomical 
information (location where specific biochemical reactions occur; 
e.g. basal ganglia of the brain) so that essential structural features 
are included along with the topological attributes.  
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